Instil Bio (TIL) FY2025 10-K Risk Factors: 16 New, 23 Dropped

What the changes say

Instil Bio shifted from clinical-stage oncology to an acquirer of early-stage assets after discontinuing multiple programs and workforce reductions.

What changed since the prior 10-K

New

NewRisks Related to our Financial Position and Capital Needs
our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products
We discontinued our tumor infiltrating lymphocyte program, ITIL-168, ITIL-306, and AXN-2510, and must rebuild capabilities if we acquire new assets.
NewRisks Related to our Financial Position and Capital Needs
We will need substantial additional funding to meet our financial obligations and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to delay or curtail our planned operations and the pursuit of our strategy
We need substantial additional funding and must in-license or acquire new product candidates to survive.
NewRisks Related to our Financial Position and Capital Needs
We have suffered, and in the future could suffer, additional losses due to impairment charges related to our Tarzana, California facility, and, in the event of a sale of such facility, the proceeds could be less than our carrying value or the amount of the secured debt encumbering the facility
We recorded $16.6 million in impairment losses on our Tarzana, California facility in 2025 and may suffer further losses upon sale.
NewRisks Related to the Development of Product Candidates
If we are successful in licensing or otherwise acquiring new product candidates, our business will be dependent on our ability to successfully complete preclinical and clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize such product candidates in a timely manner
Regulatory agencies like the FDA, MHRA, or EMA may require costly post-marketing trials or approve narrower indications than requested.
NewRisks Related to the Development of Product Candidates
If we do not achieve our plans and projected goals in the timeframes we announce, the trading price of our common stock may be negatively impacted
Failure to achieve announced business and clinical milestones on time may negatively impact our stock price and capital-raising ability.
NewRisks Related to the Manufacturing of Product Candidates
products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates
Limited cGMP manufacturing facilities and third-party scalability issues could delay our clinical trials and commercial launches.
NewRisks Related to the Manufacturing of Product Candidates
We expect to rely on third party manufacturers for any product candidates we may develop
Larger pharmaceutical competitors might secure preferential access to third-party manufacturing capacity and raw materials.
NewRisks Related to the Commercialization of Product Candidates
The availability of competitors’ products could limit the demand, and the price we are able to charge, for any product candidate we seek to develop. The inability to compete with existing or subsequently introduced drugs would have an adverse impact on our business, financial condition and prospects
Established pharmaceutical competitors with superior resources could outpace our development and limit demand for our potential products.
NewRisks Related to our Intellectual Property
technologies. Additionally, a derivation proceeding before the United States Patent and Trademark Office can be initiated by a third party to contest inventorship of the subject matter claimed in our applications
Third-party challenges, derivation proceedings, or inability to prevent design-arounds could compromise our patent protection and exclusivity.
NewRisks Related to our Intellectual Property
The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management’s attention
Defending or initiating patent litigation against well-funded competitors would drain our resources and distract management.
NewRisks Related to our Intellectual Property
our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operations
Unauthorized disclosures or breaches of confidentiality agreements by employees, contractors, or advisors could result in the loss of our trade secrets.
NewRisks Related to Legal and Regulatory Compliance Matters
There have been amendments to executive, judicial and congressional challenges to certain aspects of the ACA. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year, which began in 2013 and will remain in effect until 2032 unless additional Congressional action is taken
Government policy changes, including TrumpRx Most-Favored Nation pricing mandates, create additional pricing uncertainty.
NewRisks Related to Legal and Regulatory Compliance Matters
prevalent and continue to rise, are increasingly difficult to detect and come from a variety of sources, including traditional computer “hackers,” threat actors, “hacktivists,” organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states and nation-state-supported actors
NewRisks Related to Legal and Regulatory Compliance Matters
In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position
NewRisks Related to Legal and Regulatory Compliance Matters
laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties
NewRisks Related to Ownership of our Common Stock and our Status as a Public Company
other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions

Dropped

Dropped
Risks Associated with Our Business
General statement on recurring losses and future profitability risks.
DroppedRisks Related to our Financial Position and Capital Needs
public offering and private placements of convertible preferred stock to date. We have no products approved for commercialization and have never generated any revenue from product sales
DroppedRisks Related to our Financial Position and Capital Needs
To date, we have recorded significant impairment losses on long-lived assets. Most recently, in the year ended December 31, 2024, we recorded aggregate impairment charges of approximately $7.5 million related to our restructuring plans
DroppedRisks Related to the Development of our Product Candidates
our clinical trials are completed as planned, we cannot be certain that their results will support the safety and effectiveness of our product candidates for their targeted indications or support continued clinical development of such product candidates. Our clinical trials may not be successful
History of preferred stock offerings and preclinical development status.
DroppedRisks Related to the Development of our Product Candidates
We may seek Fast Track designation for our product candidates, and we may be unsuccessful. Even if received, Fast Track designation may not actually lead to a faster review or approval process and does not increase the likelihood that our product candidates will receive marketing approval
DroppedRisks Related to the Development of our Product Candidates
indications as one or more of our product candidates, or approved products for the conditions for which we are developing our product candidates
DroppedRisks Related to the Development of our Product Candidates
We may seek orphan drug designation for some of our product candidates, and we may be unsuccessful, or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity, for product candidates for which we obtain orphan drug designation
2024 restructuring impairment charges of $7.5 million related to the Tarzana facility.
DroppedRisks Related to the Development of our Product Candidates
Breakthrough therapy designation by the FDA for any product candidate may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that the product candidate will receive marketing approval
DroppedRisks Related to the Development of our Product Candidates
We plan to work with our collaborator, ImmuneOnco, to conduct clinical trials for AXN-2510/IMM2510 and AXN-27M/IMM27M outside the United States, including China, and the FDA and similar foreign regulatory authorities may not accept data from such trials conducted in locations outside of their jurisdiction
Uncertainty of clinical trial safety and efficacy results across different regulatory bodies.
DroppedRisks Related to the Development of our Product Candidates
If we do not achieve our plans and projected development goals in the timeframes we announce and expect, the commercialization of our products may be delayed
Risks regarding FDA Fast Track designation applications and outcomes.
DroppedRisks Related to the Development of our Product Candidates
The market opportunities for any current or future product candidate we develop, if approved, may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small
DroppedRisks Related to the Development of our Product Candidates
We may develop AXN-2510/IMM2510, AXN-27M/IMM27M and future product candidates for use in combination with other therapies or third-party product candidates, which exposes us to additional regulatory risks
DroppedRisks Related to the Manufacturing of our Product Candidates
manufacture any of our product candidates on any scale, including clinical or commercial scale. We currently plan to rely on third parties for supply of our product candidates and for commercial supply if any of our product candidates are approved for sale
DroppedRisks Related to the Commercialization of our Product Candidates
Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
DroppedRisks Related to the Commercialization of our Product Candidates
Our business and operations would suffer in the event we, or the third parties with whom we work, suffer computer system failures, cyberattacks or a deficiency in our or such third parties’ cybersecurity
DroppedRisks Related to our Intellectual Property
We depend on our relationship with, and the comprehensiveness of the intellectual property licensed from, ImmuneOnco, and termination of the IO Collaboration Agreement, or issues related to intellectual property could have a material adverse effect on our business
DroppedRisks Related to our Intellectual Property
relevant agreement, or increase our costs to develop, manufacture and commercialize products under the IO Collaboration Agreement
Clinical trial delays stemming from slow patient enrollment or patient withdrawal.
DroppedRisks Related to our Intellectual Property
violates the terms of such agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result
Risks associated with seeking Orphan Drug Designation.
DroppedRisks Related to our Intellectual Property
threatened or brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the drug or product candidate that is the subject of the actual or threatened suit
Risks associated with FDA Breakthrough Therapy Designation.
DroppedRisks Related to our Intellectual Property
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
DroppedRisks Related to our Intellectual Property
Any trademarks we have obtained or may obtain may be infringed or otherwise violated, or successfully challenged, resulting in harm to our business
Collaboration risks with ImmuneOnco regarding AXN-2510 and AXN-27M trials in China.
DroppedRisks Related to Legal and Regulatory Compliance Matters
Our collaboration with ImmuneOnco subjects us to risks and uncertainties relating to challenged and changing relations between the United States and China
DroppedRisks Related to Legal and Regulatory Compliance Matters
U.S.-China trade relations may adversely impact our supply chain operations and business
Milestone delays related to the ImmuneOnco collaboration.

Reworded

100% rewrittenRisks Related to the Development of Product Candidates
If we are unable to successfully develop, receive regulatory approval for and commercialize product candidates for the indications we seek, or experience significant delays in doing so, our business will be harmed
Updated to reflect that we currently have no active product candidates, no clinical trial experience, and no prior regulatory filings like an NDA or BLA.
Was: regulatory approval for and commercialize AXN-2510/IMM2510, or successfully develop any other product candidates, or experience significant delays in doing so, our business will be harmed
95% rewrittenRisks Related to Legal and Regulatory Compliance Matters
Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations
Retained standard healthcare reform risk language while adjusting introductory framing.
94% rewrittenRisks Related to our Financial Position and Capital Needs
We have incurred significant losses since our inception and have identified an indicator of substantial doubt about our ability to continue as a going concern. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability
Updated net loss figures for 2025 ($71.4 million), accumulated deficit ($726.5 million), and added a going concern warning.
Was: We have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability
94% rewrittenRisks Related to our Financial Position and Capital Needs
We have a limited operating history and no history of completing any clinical trial or commercializing any product, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability
Trimmed the operating history description to omit specific forward-looking prediction caveats.
93% rewrittenRisks Related to the Development of Product Candidates
Clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of any product candidate we may seek to develop
Removed specific historical references to ceased TIL trials and CoStAR-TIL technology, generalizing the risk to any future product candidates.
Was: Preclinical studies and clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of our product candidates
86% rewrittenRisks Related to the Development of Product Candidates
We may experience delays or difficulties in the enrollment and/or retention of patients in clinical trials, which could delay or prevent our receipt of necessary regulatory approvals
Generalized patient enrollment risk language from specific ongoing trials to potential future product candidates.
76% rewrittenRisks Related to our Intellectual Property
Our success depends in large part on our ability to obtain and maintain patent and other intellectual property protection in the United States and in other countries with respect to any product candidates we may seek to develop
Minor grammatical adjustments regarding future patent applications and legal uncertainties.
Was: Our success depends in large part on our ability to obtain and maintain patent and other intellectual property protection in the United States and in other countries with respect to our product candidates
72% rewrittenRisks Related to the Commercialization of Product Candidates
We face significant potential competition from other biotechnology and pharmaceutical companies, and from non-profit institutions, which may result in others identifying, discovering, developing or commercializing products before or more successfully than we do
Expanded competitor scope to include universities, public and private research institutions, and general oncology indications.
Was: We face significant competition from other biotechnology and pharmaceutical companies, and from non-profit institutions, which may result in others discovering, developing or commercializing products before or more successfully than we do
72% rewrittenRisks Related to our Financial Position and Capital Needs
Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to technologies or product candidates
70% rewrittenRisks Related to Ownership of our Common Stock and our Status as a Public Company
Unfavorable global economic and political conditions could adversely affect our business, financial condition or results of operations
70% rewrittenRisks Related to the Development of Product Candidates
As a company, we do not have experience completing clinical trials and may be unable to complete clinical trials for any product candidates we may develop
Was: As an organization, we do not have experience completing clinical trials, and may be unable to complete clinical trials for any product candidates we may develop, including AXN-2510/IMM2510
62% rewrittenRisks Related to Legal and Regulatory Compliance Matters
If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could seriously harm our business
60% rewrittenRisks Related to our Intellectual Property
Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
57% rewrittenRisks Related to the Development of Product Candidates
We may expend our limited resources to pursue a particular product candidate or indication and fail to pursue other more promising product candidates or indications that may be more profitable or for which there is a greater likelihood of success
Was: We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
52% rewrittenRisks Related to the Development of Product Candidates
We currently have no product candidate in active development. We have, and we may in the future, engage in strategic transactions to license or otherwise acquire new product candidates or technologies, and we may not be successful in developing or commercializing any such product candidates
Was: We have, and we may in the future, engage in strategic transactions to acquire or in-license additional new product candidates or technologies, and we may not be successful in developing and commercializing any product candidates we acquire or in-license, including AXN-2510/IMM2510
42% rewrittenRisks Related to the Development of Product Candidates
The regulatory approval processes of the FDA, MHRA, EMA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for product candidates we may seek to develop, our business will be substantially harmed
Was: The regulatory approval processes of the FDA, MHRA, EMA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for our product candidates, our business will be substantially harmed
38% rewrittenRisks Related to our Intellectual Property
Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain
38% rewrittenRisks Related to the Development of Product Candidates
We may fail to demonstrate with substantial evidence from adequate and well-controlled trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that product candidates we may seek to develop are safe and potent for their intended uses
Was: We may fail to demonstrate with substantial evidence from adequate and well-controlled trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that our product candidates are safe and potent for their intended uses
36% rewrittenRisks Related to Ownership of our Common Stock and our Status as a Public Company
A significant portion of our total outstanding shares are available for immediate resale. This could cause the market price of our common stock to drop significantly, even if our business is doing well
35% rewrittenRisks Related to Our Dependence on Third Parties
We may seek collaborations with third parties for the development or commercialization of any product candidates we may seek to develop. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates
Was: We are currently party to a collaboration with ImmuneOnco and may seek additional collaborations with third parties for the development or commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates
31% rewrittenRisks Related to the Commercialization of Product Candidates
The treatable populations for any product candidates we may seek to develop may be smaller than we or third parties currently project, which may affect the addressable markets for such product candidates
Was: The treatable populations for our product candidates may be smaller than we or third parties currently project, which may affect the addressable markets for our product candidates
30% rewrittenRisks Related to our Intellectual Property
Intellectual property rights do not necessarily address all potential threats to our competitive advantage
30% rewrittenRisks Related to the Development of Product Candidates
Interim, “top-line” and preliminary results from clinical trials that we may announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data
Was: Interim, “top-line” and preliminary results from our clinical trials that we or our collaborators announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data
27% rewrittenRisks Related to Ownership of our Common Stock and our Status as a Public Company
An active trading market for our common stock may not continue to be developed or sustained
27% rewrittenRisks Related to the Commercialization of Product Candidates
Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop
24% rewrittenRisks Related to Employee Matters and Managing our Growth
Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel
23% rewrittenRisks Related to the Development of Product Candidates
Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. Any product candidates we may seek to develop may not have favorable results in later clinical trials, if any, or receive regulatory approval
Was: Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. Our product candidates may not have favorable results in later clinical trials, if any, or receive regulatory approval
22% rewrittenRisks Related to Ownership of our Common Stock and our Status as a Public Company
Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment
21% rewrittenRisks Related to the Commercialization of Product Candidates
The success of any product candidates we seek to develop will depend significantly on coverage and adequate reimbursement or the willingness of patients to pay for these therapies
Was: The success of our product candidates will depend significantly on coverage and adequate reimbursement or the willingness of patients to pay for these therapies
20% rewrittenRisks Related to Ownership of our Common Stock and our Status as a Public Company
The trading price of the shares of our common stock has been and may continue to be very volatile, and purchasers of our common stock could incur substantial losses
Was: The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could incur substantial losses

All 74 risk factors

Headings as the filing states them, in filing order.

Risks Related to our Financial Position and Capital Needs

01We have incurred significant losses since our inception and have identified an indicator of substantial doubt about our ability to continue as a going concern. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability94% rewritten
02We have a limited operating history and no history of completing any clinical trial or commercializing any product, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability94% rewritten
03our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing productsNew
04We will need substantial additional funding to meet our financial obligations and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to delay or curtail our planned operations and the pursuit of our strategyNew
05Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to technologies or product candidates72% rewritten
06We have suffered, and in the future could suffer, additional losses due to impairment charges related to our Tarzana, California facility, and, in the event of a sale of such facility, the proceeds could be less than our carrying value or the amount of the secured debt encumbering the facilityNew

Risks Related to the Development of Product Candidates

07We currently have no product candidate in active development. We have, and we may in the future, engage in strategic transactions to license or otherwise acquire new product candidates or technologies, and we may not be successful in developing or commercializing any such product candidates52% rewritten
08If we are unable to successfully develop, receive regulatory approval for and commercialize product candidates for the indications we seek, or experience significant delays in doing so, our business will be harmed100% rewritten
09Clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of any product candidate we may seek to develop93% rewritten
10The regulatory approval processes of the FDA, MHRA, EMA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for product candidates we may seek to develop, our business will be substantially harmed42% rewritten
11If we are successful in licensing or otherwise acquiring new product candidates, our business will be dependent on our ability to successfully complete preclinical and clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize such product candidates in a timely mannerNew
12Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. Any product candidates we may seek to develop may not have favorable results in later clinical trials, if any, or receive regulatory approval23% rewritten
13Interim, “top-line” and preliminary results from clinical trials that we may announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data30% rewritten
14We may fail to demonstrate with substantial evidence from adequate and well-controlled trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that product candidates we may seek to develop are safe and potent for their intended uses38% rewritten
15As a company, we do not have experience completing clinical trials and may be unable to complete clinical trials for any product candidates we may develop70% rewritten
16We may experience delays or difficulties in the enrollment and/or retention of patients in clinical trials, which could delay or prevent our receipt of necessary regulatory approvals86% rewritten
17We may expend our limited resources to pursue a particular product candidate or indication and fail to pursue other more promising product candidates or indications that may be more profitable or for which there is a greater likelihood of success57% rewritten
18If we do not achieve our plans and projected goals in the timeframes we announce, the trading price of our common stock may be negatively impactedNew

Risks Related to the Manufacturing of Product Candidates

19products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidatesNew
20We expect to rely on third party manufacturers for any product candidates we may developNew
21Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay

Risks Related to the Commercialization of Product Candidates

22Even if any product candidates we may seek to develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
23If we are unable to establish sales, marketing and distribution capabilities for any product candidate that may receive regulatory approval, we may not be successful in commercializing those product candidates if and when they are approved
24The treatable populations for any product candidates we may seek to develop may be smaller than we or third parties currently project, which may affect the addressable markets for such product candidates31% rewritten
25Off-label use or misuse of any products we may seek to develop may harm our reputation in the marketplace, result in injuries that lead to costly product liability suits, and/or subject us to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with any product
26We face significant potential competition from other biotechnology and pharmaceutical companies, and from non-profit institutions, which may result in others identifying, discovering, developing or commercializing products before or more successfully than we do72% rewritten
27The availability of competitors’ products could limit the demand, and the price we are able to charge, for any product candidate we seek to develop. The inability to compete with existing or subsequently introduced drugs would have an adverse impact on our business, financial condition and prospectsNew
28The success of any product candidates we seek to develop will depend significantly on coverage and adequate reimbursement or the willingness of patients to pay for these therapies21% rewritten
29Foreign governments also have their own healthcare reimbursement systems, which vary significantly by country and region, and we cannot be sure that coverage and adequate reimbursement will be made available with respect to the treatments in which our products are used under any foreign reimbursement system
30Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop27% rewritten

Risks Related to Our Dependence on Third Parties

31We also are required to register certain ongoing clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions
32We may seek collaborations with third parties for the development or commercialization of any product candidates we may seek to develop. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates35% rewritten

Risks Related to our Intellectual Property

33Our success depends in large part on our ability to obtain and maintain patent and other intellectual property protection in the United States and in other countries with respect to any product candidates we may seek to develop76% rewritten
34technologies. Additionally, a derivation proceeding before the United States Patent and Trademark Office can be initiated by a third party to contest inventorship of the subject matter claimed in our applicationsNew
35If we fail to comply with our obligations imposed by any intellectual property licenses with third parties that we may need in the future, we could lose rights that are important to our business
36Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our future patents
37We may be involved in lawsuits to protect or enforce patents protecting product candidates we may seek to develop, which could be expensive, time consuming and unsuccessful
38We may not identify relevant third party patents or may incorrectly interpret the relevance, scope or expiration of a third party patent which might adversely affect our ability to develop and market products
39We may be unsuccessful in licensing or acquiring intellectual property from third parties that may be required to develop and commercialize our product candidates
40Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain38% rewritten
41The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management’s attentionNew
42We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties
43We may be subject to claims challenging the inventorship or ownership of our future patents and other intellectual property
44Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed60% rewritten
45our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operationsNew
46We may enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world
47Intellectual property rights do not necessarily address all potential threats to our competitive advantage30% rewritten

Risks Related to Legal and Regulatory Compliance Matters

48Even if we obtain regulatory approval for any product candidates we may seek to develop, they will remain subject to ongoing regulatory oversight, which may result in significant additional expense
49In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy
50Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations95% rewritten
51There have been amendments to executive, judicial and congressional challenges to certain aspects of the ACA. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year, which began in 2013 and will remain in effect until 2032 unless additional Congressional action is takenNew
52prevalent and continue to rise, are increasingly difficult to detect and come from a variety of sources, including traditional computer “hackers,” threat actors, “hacktivists,” organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states and nation-state-supported actorsNew
53In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market positionNew
54If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could seriously harm our business62% rewritten
55laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penaltiesNew

Risks Related to Employee Matters and Managing our Growth

56Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel24% rewritten
57Our resources may not be sufficient to manage our future growth; failure to properly manage our potential growth could disrupt our operations and adversely affect our business, financial condition, results of operations and prospects
58Our employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements

Risks Related to Ownership of our Common Stock and our Status as a Public Company

59An active trading market for our common stock may not continue to be developed or sustained27% rewritten
60The trading price of the shares of our common stock has been and may continue to be very volatile, and purchasers of our common stock could incur substantial losses20% rewritten
61If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
62A significant portion of our total outstanding shares are available for immediate resale. This could cause the market price of our common stock to drop significantly, even if our business is doing well36% rewritten
63Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result
64Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions
65We are an “emerging growth company” and a “smaller reporting company” and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors
66We will have broad discretion in the use of our cash and cash equivalents
67Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment22% rewritten
68other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictionsNew
69We have incurred and will continue to incur increased costs and demands upon management as a result of being a public company
70If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired
71Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts
72We might not be able to utilize a significant portion of our net operating loss carryforwards
73Our business activities could be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery and anti-corruption laws
74Unfavorable global economic and political conditions could adversely affect our business, financial condition or results of operations70% rewritten

Other Instil Bio 10-Ks

FY2024 10-K risk factors
81 risks
Instil Bio faces high financial losses, having accumulated $655.1 million in deficit as of December 31, 2024. The company relies heavily on its collaboration with ImmuneOnco for its lead product candidates AXN-2510/IMM2510 and AXN-27M/IMM27M. It has zero commercial products and no history of completing clinical trials.
Filed Mar 04, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.